StreetAlpha
10x Genomics, Inc. · Earnings

TXG Earnings Results and History

Latest: Q3 2026From SEC 8-K, 10-Q and 10-K filingsNext report: Feb 11, 2027

10x Genomics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← TXG stock page

Q3 2026 result
Beat on revenue
  • EPS−$0.15
  • Revenue$150.7M vs $148M est +1.8%
  • Revenue growth+1.1% vs a year ago
  • Outlook RaisedFY 2026: $625M to $635M revenue

Filed ยท Press release

Revenue growth+1.1%vs −1.7% a year ago
Operating margin−10.7%vs −21.6% a year ago
EPS beat rateFree accountlast 9 reports
Avg move afterFree accountnext day, after each report

Key takeaways

from the press release
  • Revenue rose 1% to $150.7 million, while consumables grew 5% to $134.3 million, led by single cell and spatial.
  • Gross margin improved to 75% from 67%, helped by lower inventory write-downs and a more favorable product mix.
3 more takeaways with a free account.Create free account

EPS by quarter

GAAP diluted, 12 quarters
Dec 2023: EPS -$0.41-0.41Dec '23Mar 2024: EPS -$0.50-0.50Mar '24Jun 2024: EPS -$0.32-0.32Jun '24Sep 2024: EPS -$0.30-0.30Sep '24Dec 2024: EPS -$0.41-0.41Dec '24Mar 2025: EPS -$0.28-0.28Mar '25Jun 2025: EPS $0.280.28Jun '25Sep 2025: EPS -$0.22-0.22Sep '25Dec 2025: EPS -$0.13-0.13Dec '25Mar 2026: EPS -$0.10-0.10Mar '26Jun 2026: EPS -$0.14-0.14Jun '26Sep 2026: EPS -$0.15-0.15Sep '26

Revenue and operating margin

from 10-Q and 10-K
Dec 2023: revenue $184M-30%Dec '23Mar 2024: revenue $141M-44%Mar '24Jun 2024: revenue $153.1M-27%Jun '24Sep 2024: revenue $151.7M-27%Sep '24Dec 2024: revenue $165M-30%Dec '24Mar 2025: revenue $154.9M-25%Mar '25Jun 2025: revenue $172.9M17%Jun '25Sep 2025: revenue $149M-22%Sep '25Dec 2025: revenue $166M-12%Dec '25Mar 2026: revenue $150.8M-11%Mar '26Jun 2026: revenue $151M-13%Jun '26Sep 2026: revenue $150.7M-11%Sep '26
RevenueOperating margin %

Quarter by quarter

from 10-Q and 10-K filings
Quarter endedRevenueGrowthGross marginOp marginNet incomeEPSFree cash flow
Sep 2026$150.7M+1.1%75.0%−10.7%−$19.4M−$0.15$14.9M
Jun 2026$151M−12.6%74.5%−12.9%−$17.9M−$0.14$15.4M
Mar 2026$150.8M−2.6%70.4%−11.3%−$13.5M−$0.10$24.5M
Dec 2025$166M+0.6%68.1%−11.8%−$16.3M−$0.13$39M
Create a free account to see all 12 quarters, or sign in.

EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.

Reports and price reactions

last 9 reports
How TXG moved after each of its last 9 reports, the move options priced in, and StreetAlpha's call. Free account.Create free account

Year by year

fiscal years, from 10-K filings
Year endedRevenueGrowthOp marginNet incomeEPS
Dec 31, 2025$642.8M+5.2%−9.5%−$43.5M−$0.35
Dec 31, 2024$610.8M−1.3%−31.9%−$182.6M−$1.52
Dec 31, 2023$618.7M+19.8%−42.9%−$255.1M−$2.18
Dec 31, 2022$516.4M+5.3%−32.5%−$166M−$1.46
Dec 31, 2021$490.5M–−10.7%−$58.2M−$0.53

Filings and dates

SEC EDGAR
  • Feb 11, 2027Next earnings reportexpected
  • Nov 6, 2026Quarterly report10-Q All filings
  • Nov 5, 2026Earnings release, Q3 20268-K Press release

Also see TXG institutional ownership and the earnings calendar.

TXG earnings FAQ

What were TXG's latest earnings?

For Q3 2026 10x Genomics, Inc. reported revenue of $150.7M, GAAP EPS of -$0.15. The results were filed with the SEC on Nov 5, 2026.

When is TXG's next earnings date?

10x Genomics, Inc. is expected to report on Feb 11, 2027. Dates can move until the company confirms them.

Is TXG's revenue growing?

In the quarter ended Sep 30, 2026 revenue was $150.7M, up 1.1% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.

Where do these numbers come from?

Results, guidance and financials come from 10x Genomics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.